Search
NP-50301
go.drugbank.com/drugs/DB05662ExperimentalIt is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. … The majority of sufferers of DES are postmenopausal women; and clinical research around the world has suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this
Galiximab
go.drugbank.com/drugs/DB04901InvestigationalGaliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.
Cycrimine
go.drugbank.com/drugs/DB00942ApprovedCycrimine is a drug used to reduce levels of acetylcholine to return a balance with dopamine in the treatment and management of Parkinson's disease.
TBC-3711
go.drugbank.com/drugs/DB05407InvestigationalTBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.
Metacycline
go.drugbank.com/drugs/DB00931ApprovedA broad-spectrum semisynthetic antibiotic related to tetracycline but excreted more slowly and maintaining effective blood levels for a more extended period.
Tipifarnib
go.drugbank.com/drugs/DB04960InvestigationalTipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. … It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.
Lutetium Lu177 Edotreotide
go.drugbank.com/drugs/DB17278InvestigationalCategories: Compounds used in a research, industrial, or household settingDenatonium
go.drugbank.com/drugs/DB18588InvestigationalSynonyms: Benzenemethanaminium, n-(2-((2,6-dimethylphenyl)amino)-2-oxoethyl)-n,n-diethylCategories: Compounds used in a research, industrial, or household settingXL784
go.drugbank.com/drugs/DB04991InvestigationalXL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because of its important role in blood vessel formation and cell proliferation. … It is being developed by Exelixis, Inc.
4-Hydroxytestosterone
go.drugbank.com/drugs/DB01485IllicitInvestigational[A14385] Like formestane, 4-hydroxytesterone has been patented for use in decreasing estrogen production in the body, but no such indication currently exists. 4-Hydroxytestosterone was first patented in … It is an anabolic steroid with no therapeutic indications, which is prohibited from use in sports by the World Anti-Doping Agency.